| pubmed-article:11468151 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0026986 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0035419 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0332152 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:11468151 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:11468151 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11468151 | pubmed:dateCreated | 2001-7-24 | lld:pubmed |
| pubmed-article:11468151 | pubmed:abstractText | The conditioning regimen prior to stem cell transplantation in 36 patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) was intensified by treating patients with a rhenium 188-labeled anti-CD66 monoclonal antibody. Dosimetry was performed prior to therapy, and a favorable dosimetry was observed in all cases. Radioimmunotherapy with the labeled antibody provided a mean of 15.3 Gy of additional radiation to the marrow; the kidney was the normal organ receiving the highest dose of supplemental radiation (mean 7.4 Gy). Radioimmunotherapy was followed by standard full-dose conditioning with total body irradiation (12 Gy) or busulfan and high-dose cyclophosphamide with or without thiotepa. Patients subsequently received a T-cell-depleted allogeneic graft from a HLA-identical family donor (n = 15) or an alternative donor (n = 17). In 4 patients without an allogeneic donor, an unmanipulated autologous graft was used. Infusion-related toxicity due to the labeled antibody was minimal, and no increase in treatment-related mortality due to the radioimmunoconjugate was observed. Day +30 and day +100 mortalities were 3% and 6%, respectively, and after a median follow-up of 18 months treatment-related mortality was 22%. Late renal toxicity was observed in 17% of patients. The relapse rate of 15 patients undergoing transplantation in first CR (complete remission) or second CR was 20%; 21 patients not in remission at the time of transplantation had a 30% relapse rate. (Blood. 2001;98:565-572) | lld:pubmed |
| pubmed-article:11468151 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11468151 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11468151 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11468151 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:11468151 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:BuckAA | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:SeitzUU | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:BergmannLL | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:DunckerCC | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:ReskeS NSN | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:DöhnerHH | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:WiesnethMM | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:BunjesDD | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:MunzertGG | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:KotzerkeJJ | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:StefanicMM | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:GlattingGG | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:GrimmingerWW | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:KarakasTT | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:BuchmannII | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:DohrDD | lld:pubmed |
| pubmed-article:11468151 | pubmed:author | pubmed-author:HarsdorfS VSV | lld:pubmed |
| pubmed-article:11468151 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11468151 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:11468151 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:11468151 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11468151 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11468151 | pubmed:pagination | 565-72 | lld:pubmed |
| pubmed-article:11468151 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:meshHeading | pubmed-meshheading:11468151... | lld:pubmed |
| pubmed-article:11468151 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11468151 | pubmed:articleTitle | Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. | lld:pubmed |
| pubmed-article:11468151 | pubmed:affiliation | Department of Haematology/Oncology, Ulm University Hospital, Robert-Koch-Strasse 8, 89091 Ulm, Germany. donald.bunjes@medizin.uni-ulm.de | lld:pubmed |
| pubmed-article:11468151 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11468151 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11468151 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11468151 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:11468151 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11468151 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11468151 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11468151 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11468151 | lld:pubmed |
